1_nanotechnology_presentation[1]

8/7/2019 1_Nanotechnology_Presentation[1]

1/19

Role of Nano-Biotech inGlobal Pharma Industry

Dr.Pawan [email protected]


2/19

T he Biggest thingright now in Industry just may be the

Smallest thing


3/19

16% of world wide POPULA T ION

18% of world wide MOR TALITY

20% of world wide MORBIDI TY

but only

2% of world wide GDP1% of world HEALTHCARE INVESTMENT

Disease Burden in India


4/19

Nano-Biotech Aiming to Meet UnmetMedical Needs

At present treatments available for just 10,000 of the30,000 known diseases.

Increase scope of conventional drug therapy from 500

diseases today to nearly 10 000 in future

20-30 million Europeans affected by 5000 rare diseases

Focus on more comprehensive and highly individualized

with tailor-made medical treatment.

To move from treatment towards disease prevention and

cure with improvements in diagnosis.


5/19

Meanwhile Environment is Changing

R&D productivity ?new technologies

commercialization costs

Demandingfinancial markets

Intensified competition

Industry consolidation

Intensified competition

Industry consolidation

Shorter life cycles, patent threats,regulatory issues,

healthcare cost containment

Globalization,political pressures

NGOs

FRS1


6/19

Slide 5

FRS1 Is it appropriate to show this? It looks like we are decreasing the spend. I would suggest eliminating.Fintan R . S teele, 2/ 16 /2004


7/19

Opportunities Ahead

5-6

25-26

2002 2010

US$ billion

S ource : McKinsey

Opportunities in the global market Emergence of new technologies Big phamacos willing to ally with

smaller players

Increasing cost pressures Pharma Cos willing to outsource

India being recognised as a global player

Innovation-led global opportunities (R&D )

IT -led sales and marketing opportunity

Export opportunity (Generics, bulk)U nmet needs in the domestic market

700 million people do not have access to drugs despite low pricesIncreasing urban lifestyle is giving rise to new diseases

Mass-market growth Increase access to drugs

Shaping new therapies T reat lifestyle diseases


8/19

In this Changing Environment Pharmaceutical Research is inthe Midst of a Paradigm Shift T owards Drug Discovery

Naturalproducts

andderivatives

SerendipityReceptors Enzymes

SulphanamidesAspirinPenicillins

Psychotropics

NSAIDs

H-2 Antagonist-blockers

Lipid lowerersACE inhibitors

Nano-biotech drugs for

chronic degenerativediseasesy Agingy Cancer y Inflammation

1900 1950 1960 1970 1980 1990 2000 2010+

Source: Lehman Brothers


9/19

Application of Nano-biotech in thePharmaceutical Industryy Improve sensitivity and extend present limits

of molecular diagnosticsy Enable high-throughput screeningy Shortens time to Drug development, resulting

in lower R&D costy

Optimal Drug deliveryy Diagnostic applications in clinical trials


10/19

Potential Impact of Products BuiltAround Nano-biotechy Tiny machines that roam the body, finding

and destorying viruses or cancer cellsy Superfast drug discovery at a fraction of

todays costy Ultraspecific drug targetingy

Medical devices that use biomotors withmoving parts no larger than a protein


11/19

Potential Impact of Nano-biotech onIndustryy US National Science Foundation predicts that

nano-biotech will account for half of allpharmaceutical sales within a decade

y Nanotechnology is an integral part of corporate R&D across a wide range of industries

y Since 1999 , 52% of the $ 900 million inventure capital funding for nanotechnologyhas gone to nano-biotech startups


12/19

Nano in Application

y W yeth Rapamune to prevent organrejection in kidney transplantpatients, first product approvedusing NanoCrystal technology

(August 2000)

y Merck License agreement with C Sixty todevelop drugs based on fullerene

antioxidants


13/19

Nano in Application

y B ristol-Myers Squibb Signed researchagreement withNanoSystems to applyNanoCrystal to productsthat are poorly soluble

(September 2003)License agreement withFlamel Technologies todevelop and marketB

asulin, a controlled-release, unmodifiedhuman insulin, to bedeveloped as a once-daily injection for

diabetics


14/19

Recent Milestones of the Coming toLife Sciences

T iny biochip created speeds up disease detectionT he lab on a chip speeds up diagnosis by extracting

gene information from a tiny tissue sample no bigger thana sesame seed....

T he Straits T imes, 16 January 2004Coin-sized chip detects early signs of breast cancer

It is the first step towards doctors being able to conductbreast cancer tests in their clinics.

T he Straits T imes, 13 November 2003Nano-based blood glucose strip may give more accuratereadings for diabetics

Nanobiotech News, 29 October 2003


15/19

T op 10 Nano-biotech Companies

y Immunicon Diagnostic screeningusing nanoparticles

y Quantum Dot Semiconductor nanocrystals

for biological assaysy Surface Logic Miniature biological assays

for drug discoveryy

Genicon Sciences Nanoscale signal for diagnosticsy PicoLiter Nanoparticle manufacturingSource: Nature Biotechnology, Lux Capital


16/19

T op 10 Nano-biotech Companies

y US Genomics Single molecule analysisassays for drug discovery

y Nanosphere Diagnostic nanoprobes andimage analysis

y Advion B iosciences Nanoelectrospraybioanalysis using biochipsfor drug delivery

y Ferx Drug delivery usingmagnetic forcesy Nanogram devices Nanomaterials for

biomedical applicationSource: Nature Biotechnology, Lux Capital


17/19

T otal Venture Capital raised by theT op 10 nano-biotech companies

~ $319 million

According to Lux Capitalin 2002 investment in nano-biotech

increased by 313% over investment in2001

Source: Nature Biotechnology, Lux Capital

Investments in Nano-biotech Companies


18/19

Nano-biotech:

the Future of Pharma

Research?


19/19

Z epto

Atto

Nano

1_nanotechnology_presentation[1]

Documents